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Comorbidities impair the prognosis of diffuse large B-cell lymphoma (DLBCL). Type 2 diabetes mellitus 
(DMT2) increases the risk of other comorbidities, e.g., heart failure (HF). Thus, we hypothesized 
that pre-existing DMT2 may negatively affect the outcome of DLBCL. To verify this, DLBCL patients 
treated with (R)-CHOP were enrolled. 469 patients were eligible, with a median age of 57 years; 356 
patients had advanced-stage DLBCL. 126 patients had high-intermediate and 83 high-risk international 
prognostic index (IPI). Seventy-six patients had DMT2, 46 HF; 26 patients suffered from both DMT2 
and HF. In the analyzed group DMT2 or HF significantly shortened overall survival (OS) and progression 
free survival (PFS): the 5-year OS for patients with DMT2 was 64% vs 79% and for those with HF: 49% vs 
79%. The 5-year PFS for DMT2 was 50.6% vs 62.5% and for HF 39.4% vs 63.2%. The relapse/progression 
incidence was comparable between groups; the non-relapse/progression mortality (NRPM) was 
significantly higher solely in DMT2 patients (5-year NRPM 22.5% vs 8.4%). The risk of death was higher 
in patients with higher IPI (HR = 1.85) and with DMT2 (HR = 1.87). To conclude, pre-existing DMT2, in 
addition to a higher IPI and HF, was a negative predictor for OS and PFS.
Pre-existing comorbidities create an additional challenge in lymphoma management. First, comorbidities 
increase the risk of treatment-related complications, and second, treatment itself aggravates their clinical course1. 
As a consequence, lymphoma and comorbidities act as competing risks for death in respective patients. In 
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addition, comorbidities influence treatment decision-making in daily practice, which may indirectly affect treat-
ment outcomes2.
The anthracycline-based chemotherapy R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, 
prednisone) is the current standard treatment for diffuse large B-cell lymphoma (DLBCL). Doxorubicin is car-
diotoxic and leads to chronic heart failure3,4 and premature cardiovascular mortality, mainly in patients with 
preexisting cardiovascular disorders5–7. The steroids in R-CHOP exacerbate type 2 diabetes mellitus (DMT2), 
which further deteriorates cardiovascular disorders. Thus, the presence of DMT2 at diagnosis may also increase 
R-CHOP cardiotoxicity and impair prognosis. Additionally, diabetes increases the risk of infections and com-
promises the immune content of the tumor8,9. Therefore, we hypothesized that pre-existing DMT2 negatively 
affects the outcomes of DLBCL patients. To verify this hypothesis, the Polish Lymphoma Research Group (PLRG) 
launched a retrospective study aimed at evaluating the impact of pre-existing DMT2 on the survival of DLBCL 
patients treated with R-CHOP chemotherapy.
Materials and Methods
This study was approved by the Ethical Board of the Medical University of Warsaw and was performed in accord-
ance with the Declaration of Helsinki. Eligible for this retrospective study were patients diagnosed with DLBCL 
who received R-CHOP or CHOP, at the intended full dose, at nine participating PLRG centers between 2000–
2017. The patients gave informed consent for treatment and the follow-up analysis. No additional consent was 
obtained for this retrospective analysis of the data.
Treatment. Patients received R-CHOP (rituximab 375 mg/m2 day 1, cyclophosphamide 750 mg/m2 day 1, 
vincristine 2 mg day 1, doxorubicin 50 mg/m2 day 1 and prednisone 40 mg/m2 days 1 through 5; every 21 days) 
or CHOP. Supportive treatments (prevention of tumor lysis syndrome; febrile neutropenia prophylaxis; anti-
bacterial, antifungal, and antiviral prophylaxis and therapy; and blood products) were administered according 
to the local standards. The response to chemotherapy treatment was evaluated according to Cheson criteria10. 
The overall response rate (ORR) was defined as the best response comprising complete response (CR) or partial 
response (PR).
Statistical analysis. The analyzed data, i.e., age, sex, disease stage, international prognostic index (IPI)11, 
and coexistence of DMT2 or HF, defined by typical clinical symptoms and confirmed by routine echocardiogra-
phy12, were obtained from the medical records. In addition, cardiovascular risk factors, i.e., obesity, smoking, lipid 
abnormalities and coexistence of arterial hypertension or chronic kidney failure/nephropathy (collected solely for 
DMT2 patients) at diagnosis, were collected. Steroid-induced hyperglycemia or diabetes that developed during 
treatment was not classified as DMT2 for the purpose of the study.
Continuous variables are presented as median values (and their range), while frequency tables were used 
for categorical variables. The patients’ characteristics were compared between groups with the use of two-sided 
Fisher’s exact test for categorical variables and the Mann-Whitney test for continuous variables. The primary 
endpoint was overall survival (OS) estimated by the Kaplan-Meier method, and differences in subgroups were 
assessed by the log-rank test. Secondary endpoints were progression-free survival (PFS) estimated by the 
Kaplan-Meier method and relapse/progression incidence and non-relapse/progression mortality (NRPM), each 
estimated using cumulative incidence rates to accommodate competing risks, were compared by Gray’s test; for 
relapse/progression, we considered death without relapse/progression as a competing event and vice versa. Each 
of the primary and secondary endpoints was evaluated at 5 years along with 95% confidence intervals (95% CIs).
All risk factors important for survival in the univariate analysis (p < 0.1) were subsequently analyzed in the 
multivariate model using proportional hazards Cox regression. Backward selection was used to identify the most 
significant predictive factors. Assumptions of the Cox model were verified with the test for proportional hazards. 
The results were considered to be significant when p < 0.05.
To confirm the negative impact of DMT2 on OS, a case-matched analysis with propensity score inverse 
weighting was performed, as described by Imbens13,14. First, diabetes patients were balanced for age and IPI, and 
then a Cox regression model was used to analyze the impact of diabetes. All calculations were performed using R, 
version 3.2.2 l. Plots were generated with the ggplot2 package.
Results
Study population and patient characteristics. Our study included 469 patients with DLBCL treated 
with R-CHOP (424; 90%) or CHOP (45; 10%). The median age at diagnosis was 57 years (range: 18–86). The 
majority of patients (356, 76%) had an advanced stage (III and IV) of lymphoma. At diagnosis, 76 (16.2%) 
patients had DMT2, 46 (9.8%) had pre-existing HF, and none of them had type 1 diabetes mellitus. Most of the 
patients had diastolic HF with a preserved ejection fraction (EF); only 4 (8.7%) had mid-range EFs and 1 (2.2%) 
had a reduced EF12. DMT2 and HF were strongly associated with each other; 26 patients (34% of all patients 
with DMT2 and 56.5% of those with HF) suffered both from DMT2 and HF. Chronic kidney failure/nephrop-
athy was concurrent in 15 out of 68 DMT2 patients for whom data were available (22%). The median age of the 
patients with DMT2 and HF was 69 years (range: 47–86) and 71 years (range: 33–85), respectively, and they 
were significantly older than patients without any comorbidities (53 years, range: 18–86) (p < 0.05). Patients with 
either DMT2 or HF had more frequent lipid abnormalities (p < 0.05). Additionally, patients with DMT2 were 
more frequently obese (27.6%; p < 0.05) and suffered from arterial hypertension more often (78%; p < 0.05). 
Otherwise, the cohort with comorbidities was fully comparable to the control group of patients without DMT2 or 
HF (Table 1). The median time of follow-up of surviving patients was 1.9 years (0.2–16.3).
Response to therapy. The overall response rate was 91.5%, including 73.1% CRs and 18.3% PRs. The 
response rates were not different between patients with DMT2 or pre-existing HF and the control group. In 
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the entire cohort, 28 (6.0%) patients experienced progressive disease (PD); the same frequency was observed in 
patients with and without comorbidities (Table 2).
Survival analysis. Risk factor analysis. The projected 5-year OS for DMT2 patients was 64% (95% CI, 
51–80) and for non-DMT2 patients was 79% (95% CI, 72–85), p = 0.01. The median OS was not reached during 
the observation time for either group (Fig. 1); the effect of diabetes on OS in different age categories is shown in 
Fig. 2. For patients with pre-existing HF, 5-year OS was significantly inferior (49%; 95% CI, 29–81) compared 
to those without HF (79%; 95% CI, 73–85; p = 0.002). The median OS of patients with pre-existing HF was 4.65 
years (95% CI, 4.5-NA) and was not reached for patients without HF.
The projected 5-year PFS for DMT2 and non-DMT2 patients was 50.6% (95% CI, 38.2–67.2) and 62.5% (95% 
CI, 54.9–71.1), respectively, and the median PFS reached 5.06 years (95% CI, 2.68-NA) and 9.02 years (95% CI, 
6.06-NA), respectively (p = 0.036). For patients with pre-existing HF, 5-year PFS was significantly worse (39.4%; 
95% CI, 22.8–68.3) compared to those without HF (63.2%; 95% CI, 56.4–70.7), with a median PFS of 4.03 (95% 
CI, 1.15-NA) and 7.41 years (95% CI, 6.06-NA), respectively (p = 0.014).
Both univariate and multivariate analyses were performed to determine the effects of the analyzed comor-
bidities and lymphoma-specific factors on OS and PFS. The presence of DMT2, pre-existing HF, and IPI were 
significant for OS by univariate analysis with hazard ratios (HR) for DMT2, pre-existing HF, and IPI of 1.9 (95% 
Number of patients (frequency)
All patients
Patients 
with DM2 p
Patients with 
HF p
Patients without 
analyzed comorbidities p
Number of patients 469 76 — 46 — 373 —
Sex
0.45 1 0.91Female 245 (52.2%) 43 (56.6%) 24 (52.2%) 194 (52%)
Male 224 (47.8%) 33 (43.4%) 22 (47.8%) 179 (48%)
Age 57 (18–86) 69 (47–86) <0.0001 71 (33–85) <0.0001 53 (18–86) <0.0001
Rituximab
0.2 0.6 0.25Yes 424 (90.4%) 72 (94.7%) 43 (93.5%) 334 (89.5%)
No 45 (9.6%) 4 (5.3%) 3 (6.5%) 39 (10.5%)
Stage
0.66 0.15 0.69
I 17 (3.6%) 4 (5.3%) 3 (6.5%) 13 (3.5%)
II 96 (20.5%) 16 (21%) 4 (8.7%) 79 (21.2%)
III 118 (25.1%) 20 (26.3%) 12 (26.1%) 93 (24.9%)
IV 238 (50.8%) 36 (47.4%) 27 (58.7%) 188 (50.4%)
General symptoms
0.42 0.25 1
Present 313 (66.7%) 47 (61.8%) 34 (73.9%) 249 (66.8%)
Absent 150 (32%) 27 (35.5%) 11 (23.9) 120 (32.2%)
Missing 6 (1.3%) 2 (2.6%) 1 (2.2%) 4 (1%)
IPI
0.088* 0.00005* 0.0024*
0 16 (3.4%) 2 (2.6%) 2 (4.3%) 14 (3.8%)
1 76 (16.2%) 9 (11.9%) 2 (4.3%) 66 (17.7%)
2 115 (24.5%) 17 (22.4%) 4 (8.7%) 97 (26%)
3 126 (26.9%) 20 (26.3%) 14 (30.4%) 100 (26.8%)
4 75 (16.0%) 20 (26.3%) 17 (37%) 47 (12.6)
5 8 (1.7%) 2 (2.6%) 2 (4.3%) 6 (1.6%)
Missing 53 (11.3%) 6 (7.9%) 5 (11%) 43 (11.5)
Median 3 3 3 2
Mean ± SD 2.5 ± 1.2 2.8 ± 1.2 3.2 ± 1.2 2.4 ± 1.1
Type 2 diabetes mellitus 76 (16.2%) — — 26 (56.5%) <0.0001 0 (0%) <0.0001
Pre-existing heart failure 46 (9.8%) 26 (34.2%) <0.0001 — — 0 (0%) <0.0001
Lipid abnormalities 69 (14.7%) 21 (27.6%) 0.0011 15 (32.6%) 0.0013 43 (11.5%) 0.00028
Obesity 88 (18.8%) 21 (27.6%) 0.034 10 (21.7%) 0.56 62 (16.6%) 0.018
Smoking 88 (18.8%) 14 (18.4%) 1 8 (17.4%) 1 70 (18.8%) 0.88
Arterial hypertension 176 (37.5%) 59 (77.6%) <0.0001 18 (39.1%) <0.0001 105 (28.2%) <0.0001
Nephropathy
NA — — NA —
Present 15 (20%) 5 (11%)
Absent 53 (70%) 17 (37%)
Missing 8 (11%) 24 (52%)
Table 1. Baseline demographics of DLBCL patients and prevalence of comorbidities at diagnosis (SD – 
standard deviation; NA – not available). *IPI was compared 0–2 vs 3–5.
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CR PR SD PD
Total 343 (73.1%) 86 (18.3%) 12 (2.6%) 28 (6.0%)
DMT2 (n = 76) 57 (75%) p > 0.05 11 (14.5%) p > 0.05 3 (3.9%) p > 0.05 5 (6.6%) p > 0.05
Heart failure (=46) 31 (67.4%) p > 0.05 10 (21.7%) p > 0.05 2 (4.4%) p > 0.05 3 (6.5%) p > 0.05
Neither DMT2 nor HF 
(=373) 274 (73.5%) 69 (18.5%) 8 (2.1%) 22 (5.9%)
Table 2. Response to (R)-CHOP in DLBCL patients. The data is presented for the entire group and separately 
for patients afflicted with type 2 diabetes mellitus or heart failure.
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Figure 1. Overall survival of DLBCL patients with (DM) and without type 2 diabetes mellitus (no DM).
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Figure 2. Impact of diabetes on overall survival in different age group categories.
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CI, 1.2–3.2), 2.5 (95% CI, 1.4–4.4) and 2.5 (95% CI, 1.4–4.3), respectively. The effect of chronic kidney failure/
nephropathy was analyzed solely for DMT2 patients, with HR 1.81 (95% CI, 0.64–5.08; p = 0.26). In the multi-
variate analysis, which included DMT2, HF and IPI, only IPI remained significant (HR 2.2; 95% CI, 1.3–3.90; 
p = 0.0052); however, in two factor models (IPI and DMT2 or IPI and pre-existing HF) all factors remained 
significant for OS with respective HR: DMT2–1.89 (95% CI, 1.1–3.3), p = 0.022; IPI – 2.32 (95% CI, 1.3–4.1), 
p = 0.003; and HF – 2.5 (95% CI, 1.3–4.7), p = 0.004, IPI – 2.26 (95% CI, 1.3–4.0), p = 0.004. For PFS, lymphoma 
stage and IPI, as well as the presence of diabetes and pre-existing heart failure, were significant by univariate 
analysis. In the multivariate analysis that included DMT2, HF and IPI, only IPI remained significant (HR – 2.6, 
95% CI, 1.7–3.9, p = <0.001); the respective hazard ratios for DMT2 and HF were 1.3 (95% CI, 0.8–2.2) and 1.4 
(95% CI, 0.8–2.6). Similarly, when two factor models (IPI and DMT2 or IPI and pre-existing HF) were analyzed, 
only IPI retained its statistical significance: DMT2 – HR = 1.5 (95% CI, 0.95–2.3), p = 0.08, IPI – HR = 2.6 (95% 
CI, 1.7–4.0), p = <0.001; and HF – HR = 1.6 (95% CI, 0.95–2.8), p = 0.076, IPI – HR = 2.6 (95% CI, 1.7–4.0), 
p = <0.001. Detailed results of the univariate analysis are presented in Table 3. Importantly, we did not include 
age and lymphoma stage, which were significant for OS in univariate analysis, or lymphoma stage, which was 
significant for PFS, in the multivariate model, as both these characteristics were already incorporated into the 
compound IPI score, which was included.
Cause of death. Competing risks analysis. Seventy-three patients (15.6%) died. Mortality was much 
higher in patients suffering from DMT2 (22 out of 76 patients; 29%) and HF (14 out of 46 patients; 30%) patients 
than in patients without any of the analyzed comorbidities (44 out of 373; 12%). Lymphoma progression and 
cardiovascular complications were the leading causes of death in all patient groups (Table 4).
The 5-year relapse/progression rates, estimated by means of competing risk analysis, were 26.8% (95% CI, 
17.3–41.6) and 29.1% (95% CI, 22.4–37.8) for DMT2 and non-DMT2 patients (p > 0.05), respectively, while the 
5-year non-relapse/progression mortality rates were 22.5% (95% CI, 13.1–38.8) and 8.4% (95% CI, 5.3–13.4) 
for DMT2 and non-DMT2 patients, respectively (p = 0.008) (Fig. 3). The corresponding values for pre-existing 
heart failure were as follows: 5-year relapse/progression rates were 37.6% (95% CI, 22–64.1) and 26.8% (95% 
CI, 21.2–33.7) for patients with and without pre-existing HF (p > 0.05), respectively, and 5-year non-relapse/
Variable
Overall survival
HR (95% CI) p
Rituximab (yes vs no) 1.51 (0.7–3.2) 0.28
Sex (male vs female) 1.1 (0.7–1.8) 0.66
Lymphoma stage
I, II vs III, IV 3.1 (1.5–6.4) 0.003
Age (as a categorical value)
(>50 and ≤60) vs <50
>60 vs <50
1.2 (0.6–2.3)
2.1 (1.2–3.6)
0.57
0.01
IPI
1–2 vs 3–5 2.5 (1.4–4.3) 0.001
Type 2 diabetes mellitus 1.9 (1.2–3.2) 0.01
Pre-existing HF 2.5 (1.4–4.4) 0.002
Hypertension 1 (0.6–1.6) 0.95
Lipid abnormalities 0.8 (0.4–1.6) 0.44
Obesity 0.9 (0.5–1.6) 0.76
Smoking 1.1 (0.6–1.9) 0.69
Progression-free survival
Rituximab (yes vs no) 0.85 (0.5–1.4) 0.53
Sex (male vs female) 1.25 (0.9–1.8) 0.23
Lymphoma stage
I, II vs III, IV 2.5 (1.5–4.3) <0.001
Age (as a categorical value)
(>50 and ≤60) vs <50
>60 vs <50
1.0 (0.6–1.6)
1.3 (0.9–2.0)
1.0
0.16
IPI
1–2 vs 3–5 2.7 (1.8–4.1) <0.001
Type 2 diabetes mellitus 1.6 (1.03–2.4) 0.036
Pre-existing HF 1.9 (1.1–3.1) 0.014
Hypertension 1.0 (0.7–1.5) 0.83
Lipid abnormalities 0.9 (0.5–1.7) 0.77
Obesity 0.8 (0.5–1.3) 0.43
Smoking 1.3 (0.8–1.9) 0.28
Table 3. Prognostic factors of overall survival and progression-free survival based upon univariate analysis 
presented as hazard ratios with 95% confidence intervals.
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progression mortality rates were 23% (95% CI, 10.1–52.4) versus 10% (95% CI, 6.6–15.1) for patients with and 
without pre-existing HF, respectively (p > 0.05).
Inverse propensity score weighting. To verify the hypothesis that DMT2 DLBCL patients had inferior 
OS outcomes, inverse propensity score weighting was performed. For a single agent model, including only DMT2, 
the risk of death was higher for patients with DMT2 (HR = 1.8; 95% CI, 1.3–2.7; p < 0.001); for a model encom-
passing both DMT2 and IPI, the risk of death was higher in patients with higher IPI (HR = 1.87; 95% CI; 1.3–2.66; 
p < 0.001) and DMT2 patients (HR = 1.85; 95% CI, 1.29–2.66; p < 0.001).
Progression-free survival was also influenced by IPI and diabetes. In a single agent model, including only 
DMT2, the risk of an event was higher for patients with DMT2 (HR = 1.5; 95% CI, 1.1–2.18; p = 0.013); diabetes 
retained its prognostic value in a model encompassing both DMT2 and IPI, and the results were as follows: IPI 
HR = 2.15 (95% CI; 1.5–3.0) p = <0.001, DMT2 – HR = 1.2 (95% CI, 1.06–2.11), p = 0.02.
Discussion
It is well documented that cardiovascular diseases pose a risk to lymphoma patients treated with anthracyclines5. 
However, data on the impact of diabetes on outcomes in these patients are limited and not clear. Lin and col-
leagues investigated the effect of preexisting diabetes on the survival of all lymphoma patients and showed that 
the risk of death was time-dependent and increased with prolonged time from diagnosis; the risk of death was 20 
times higher at 48 months in comparison to at 14 months of follow-up15. Tseng et al. demonstrated the association 
between the increased mortality rate ratio and younger age in diabetic patients who developed non-Hodgkin lym-
phoma16, whereas Lu et al. showed that diabetes was an adverse prognostic factor for patients treated with CHOP 
chemotherapy but, interestingly, not for patients treated with R-CHOP17. The other data on comorbidities came 
Number of 
deceased patients
Cause of death
Lymphoma 
progression
Cardiovascular 
complications Infections Undetermined
DMT2 22 (29%) 8 (36.4%) 5 (22.7%) 2 (9.1%) 7 (31.8%)
HF 14 (30%) 4 (28.6%) 6 (42.9%) 0 (0%) 4 (28.6%)
Neither DMT2 nor HF 44 (12%) 19 (43.2%) 13 (29.5%) 0 (0%) 12 (27.3%)
Total 73 (15.6%) 28 (38.4%) 24 (32.9%) 2 (2.7%) 19 (26%)
Table 4. The frequency of death and the reason of death in according to the presence of HF and DMT2.
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Figure 3. Relapse/progression incidence and non-relapse/progression mortality in DMT2 and non-DMT2 
patients.
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from studies utilizing comorbidity indices, e.g.18–25, and covered mostly elderly patients, which could have allowed 
only for speculation on the impact of diabetes in all DLBCL patients (including younger patients). Therefore, we 
launched a retrospective study to determine the impact of DMT2 on the outcomes of DLBCL patients.
In our patients, OS for patients with DMT2 was inferior to the results reported by Lu et al. (69.8%) for patients 
treated with R-CHOP17; however, OS in the current study was better than the OS reported by Kobayashi et al. 
(3-year OS 55%) and Wieringa et al. (5-year OS 48%) for elderly patients with a high comorbidity burden assessed 
by the Charlson Comorbidity Index (CCI ≥2); diabetes mellitus and peripheral and cerebrovascular diseases were 
the main contributors to the high CCI scores in these studies18,22.
Our results strongly support the negative independent impact of DMT2 on OS. First, the negative impact 
observed was independent of the IPI and independent of the presence of pre-existing HF since both factors 
(DMT2 and HF) in the two-factor models (IPI and DMT2 or IPI and pre-existing HF) remained significant 
for OS. This resulted from the fact that more than half of the patients with HF (57%) also had DMT2. However, 
chronic kidney failure/nephropathy, which often complicates the DMT2 course, did not worsen the outcome of 
diabetic patients.
Second, in our study, unlike in the studies of Kobayashi et al. and Wieringa et al., in which shortened OS was 
the result of a lower overall response rate18,22, excess mortality resulted mostly from non-relapse/progression 
mortality, as shown by the competing risk analysis. The response rates in both DMT2 and HF patients did not 
differ from those in the control patients and remained in line with the responses reported by Lu et al. in diabetic 
patients17 and by Saygin et al. in patients with high and low CCI scores21.
Third, the applied propensity score analysis with inverse weighing confirmed that increased mortality in the 
DMT2 group did not result from higher age and a naturally higher chance of dying. In both the single agent 
model and the model including both DMT2 and IPI, DMT2 was predictive for inferior overall survival. The rate 
of death for patients with diabetes was 1.78 times higher than for patients without this condition.
The excess mortality in our group was associated with increased non-relapse/progression mortality. 
Unfortunately, we were not able to identify any distinguishing cause of death in these patients; the rate of cardio-
vascular events and lymphoma progression, the most frequent causes of death, were comparable between patients 
with and without analyzed comorbidities, though there was a trend for more frequent cardiovascular deaths in 
patients with a history of heart failure. However, it is worth remembering that approximately 30% of patients with 
DMT2 and HF had an undetermined direct cause of death (in comparison to 22.7% of patients without these 
disorders), which suggests that it is still possible that preexisting diabetes could have contributed to death by 
induction of its late effects, including cardiovascular events, as shown by van de Schans et al.26, or infections, as 
documented for patients with high CCI score by Dendle et al.27. It is worth noting that the increased non-relapse/
progression mortality precluded the event of relapse, which could have been much higher if the competing event 
i.e., non-relapse/progression mortality had not occurred.
Interestingly, in patients with HF, inferior outcomes might be due to both an increased risk of non-relapse/
progression mortality related to more frequent cardiovascular deaths and an increased incidence of relapse/pro-
gression, although the p values for both events did not reach statistical significance. We do not have data to 
explain the latter phenomenon, but we may speculate that DLBCL patients with HF experienced inferior relative 
treatment intensity, which did not translate into a lower response rate, but it led to relapse/progression in the later 
course of the disease.
There are some important limitations to our study. First, there was a long period of enrollment, with changing 
lymphoma supportive treatment and changing diabetes mellitus and HF treatment. Importantly, however, the rate 
of death was comparable throughout the enrollment period. The second limitation of the study was the relatively 
young age of our patients compared to the typical DLBCL population28. One of the possible explanations is that 
elderly patients with significant comorbidities were not qualified for R-CHOP and received anthracycline-free 
chemotherapy regimens, a phenomenon already reported in the literature6,29,30. Finally, detailed information on 
the cause of death was missing for a substantial proportion of patients. This is an important limitation of our 
study. Nevertheless, it may be anticipated, however, that these deaths were mostly attributed to nonlymphoma 
causes, since relapsing and progressing patients are usually referred to their treating hematological centers.
Nevertheless, we believe that we can safely conclude that the presence of type 2 diabetes mellitus, in addition 
to cardiovascular diseases, is associated with an inferior outcome in DLBCL patients treated with (R)-CHOP. The 
negative impact of DMT2 on outcome results from an increased risk of non-relapse/progression mortality, indi-
cating the likely indirect role of DMT2 in increasing other comorbidities, especially cardiovascular disorders. To 
improve long-term results, patients with DMT2 require a multidisciplinary therapeutic approach, and a diabetes 
team should be included at each step of lymphoma and postlymphoma treatment.
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